Lentiviral Vectors
APAC · 1 shared keyword
APAC Gene Editing Market Industry Trends and Forecast to 2034: Segmented by (Technology, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
APAC · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$1.46 Bn
Estimated value
Estimate 2025
$1.74 Bn
22.3% of the global market
Projected 2034
$8.53 Bn 389.5%
Adds $6.79 Bn over 9 forecast years
CAGR 2025–2034
19.3%
Faster than 83% of 180 Pharmaceuticals markets here
Key players
6
Companies profiled
- APAC is 22.35% of the global market.
- Among regions, the largest is North America at $3.56 Bn.
- Fastest growing: APAC (this report) at 19.3% a year.
- APAC ranks 2nd of 6 by size among regions.
Market size projection
APACSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$6.79 Bn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.46 Bn | — | — |
| 2025 (base) | $1.74 Bn | +$281.9 Mn | — |
| 2026 (forecast) | $2.08 Bn | +$336.3 Mn | +19.3% |
| 2027 (forecast) | $2.48 Bn | +$401.2 Mn | +42.3% |
| 2028 (forecast) | $2.96 Bn | +$478.6 Mn | +69.8% |
| 2029 (forecast) | $3.53 Bn | +$571.0 Mn | +102.6% |
| 2030 (forecast) | $4.21 Bn | +$681.2 Mn | +141.7% |
| 2031 (forecast) | $5.02 Bn | +$812.6 Mn | +188.3% |
| 2032 (forecast) | $5.99 Bn | +$969.5 Mn | +243.9% |
| 2033 (forecast) | $7.15 Bn | +$1.16 Bn | +310.3% |
| 2034 (forecast) | $8.53 Bn | +$1.38 Bn | +389.5% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $7.80 Bn
- North America $3.56 Bn
-
US
$3.01 Bn
- APAC (this report) $1.74 Bn
- Europe $1.41 Bn
-
Canada
$615.2 Mn
-
China
$546.4 Mn
-
Japan
$424.3 Mn
- Latin America $405.9 Mn
- Middle East $353.7 Mn
-
Germany
$296.6 Mn
-
France
$208.2 Mn
-
Brazil
$191.9 Mn
-
UK
$178.9 Mn
-
Italy
$179.8 Mn
-
Spain
$153.9 Mn
-
Ecuador
$150.2 Mn
-
Saudi Arabia
$149.7 Mn
- Africa $135.9 Mn
-
Mexico
$131.4 Mn
-
India
$128.5 Mn
-
Australia
$96.8 Mn
-
Russia
$83.5 Mn
-
New Zealand
$83.5 Mn
-
South Africa
$53.6 Mn
-
UAE
$40.2 Mn
-
Egypt
$23.3 Mn
-
Philippines
$14.9 Mn
-
Hong Kong
$13.7 Mn
-
Malaysia
$11.8 Mn
-
Singapore
$10.3 Mn
-
Thailand
$9.2 Mn
-
Kenya
$5.2 Mn
The APAC Gene Editing Market Analysis Executive Summary
Gene editing tools such as CRISPR, base editing and prime editing change DNA inside cells to fix or switch off faulty genes.
Key segments of the gene Editing market include technology (CRISPR-Cas9, Base Editing and Prime Editing) and application (Therapeutics, Research and Agriculture).
APAC Gene Editing Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Editing market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Editing market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Editing market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Gene Editing Market in APAC
The gene Editing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
- CRISPR Therapeutics
- Vertex Pharmaceuticals
- Intellia Therapeutics
- Beam Therapeutics
- Editas Medicine
- Verve Therapeutics
Healthcare Policies and Regulatory Landscape for Gene Editing Market in APAC
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Editing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.